Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875469 | 0.83 | SMN1; SMN2 (0.40) | CCR5SMN1; SMN2MAPTALOX15HTT | |
| SCHEMBL6878390 | 0.81 | MAPT (0.40) | CCR5SMN1; SMN2MAPTALOX15HTT | |
| SCHEMBL3053533 | 0.80 | MAPT (0.52) | SMN1; SMN2MAPTALOX15MEN1KMT2A | |
| SCHEMBL4574907 | 0.79 | EPHX1 (0.57) | CCR5SMN1; SMN2MAPTALOX15MEN1 | |
| SCHEMBL5563645 | 0.74 | MAPT (0.35) | SMN1; SMN2MAPTALOX15HTTMEN1 | |
| SCHEMBL5559741 | 0.74 | MAPT (0.46) | SMN1; SMN2MAPTALOX15MEN1KMT2A | |
| SCHEMBL5044211 | 0.72 | HTT (0.44) | CCR5SMN1; SMN2HTTALDH1A1PDE4D | |
| SCHEMBL6878049 | 0.71 | ALDH1A1 (0.41) | SMN1; SMN2MAPTHTTHDAC1HDAC8 | |
| SCHEMBL5713585 | 0.71 | HDAC1 (0.42) | SMN1; SMN2MAPTHTTHDAC1HDAC8 | |
| SCHEMBL5044212 | 0.71 | PDE4B (0.40) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2008052930-A2 | PREPARATION OF 4-ALK0XY-7- (TETRAHYDROPYRAN-4-YL) BENZOTHIAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108826-A1 | PREPARATION OF 4-ALKOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YLAMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1636223-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-7304058-B2 | For therapy of Alzheimer's disease, depression | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1628662-B1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR | HOFFMANN LA ROCHE (CH) | 2007-02-14 | — | — | EP | disclosed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| EP-1628662-A1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| EP-1456202-B1 | BENZOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004103367-A1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATES TO THE ADENOSINE A2A RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20040235842-A1 | Carbamic acid esters of benzothiazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| EP-1456202-A1 | BENZOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6734179-B2 | SULFUR COMPOUNDS SUCH AS 4-FLUORO-N-(4-METHOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YL) -BENZAMIDE, USED AS PREFERENTIAL ADENOSINE RECEPTOR LIGANDS FOR THE PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030144288-A1 | Benzothiazoles | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| WO-2003053961-A1 | BENZOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | CCR5 1729/4885SMN1; SMN2 802/4885MAPT 252/4885 |
| US-20040235842-A1 | Carbamic acid esters of benzothiazoles | ADORA2A, ADORA1, ADORA2B | CCR5 533/4885SMN1; SMN2 2839/4885MAPT 3686/4885 |
| US-20080108826-A1 | PREPARATION OF 4-ALKOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YLAMINE DERIVATIVES | HTR7, HTR4, BRD7 | CCR5 3810/4885SMN1; SMN2 2466/4885MAPT 290/4885 |
| US-20030144288-A1 | Benzothiazoles | ADORA2A, ADORA1, ADORA2B | CCR5 1226/4885SMN1; SMN2 2702/4885MAPT 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.